PTC Therapeutics (PTCT) Director Schmertzler Sells $149K of Stock

Inside Michael Schmertzler's PTC Therapeutics Trade

Michael Schmertzler, a director at PTC Therapeutics, Inc. (NasdaqGS: PTCT), sold 2,500 shares of the biopharmaceutical company on October 14, 2026. According to a Form 4 filed with the Securities and Exchange Commission, the shares went for an average price of $59.61, bringing the total value of the transaction to $149,036.75. The trade was executed under a pre-arranged Rule 10b5-1 trading plan. On the day of the sale, PTC Therapeutics stock closed at $59.67.

Other Institutional Activity in PTC Therapeutics

Institutional investors have adjusted their positions in the biotech firm over recent months. RTW Investments LP kept its holdings steady at 7,746,415 shares worth about $458,897,637. Meanwhile, Jupiter Topco LLC increased its stake by 3,618,201 shares, ending the period with 7,236,402 shares valued at roughly $428,684,466. On the selling side, Burney Co. cut its entire position, unloading 37,320 shares to exit the stock entirely.

PTC Therapeutics, Inc. Stock Down 2.9%

Shares of PTC Therapeutics recently traded around $59.22 as of October 16, 2026. That puts the stock roughly 0.8% below its closing price on the day of the director's sale and close to its 52-week low of $58.80. The company carries a market capitalization of roughly $4.94 billion and a beta of 0.489.

Recent Earnings

PTC Therapeutics reported $1.01 billion in trailing twelve-month revenue, alongside a net profit margin of -3.8% and basic earnings per share of -$0.62. The company's next earnings report is slated for October 29, 2026.

Insider Buying and Selling at PTC Therapeutics, Inc.

Insider activity at the firm includes a few notable transactions ahead of this sale. Chief Technical Officer Neil Gregory Almstead bought 5,323 shares at $38.10 on June 24, 2026, and later sold 8,130 shares at $85.26 on June 26 under a planned schedule, alongside another purchase of 8,130 shares at $38.10 that same day. More recently, Executive VP and CLO Mark Boulding sold 192 shares at $64.26 on October 9, 2026, in a planned trade.

Analysts Set New Price Targets

Wall Street firms have updated their outlooks on the stock in recent months. Morgan Stanley maintained an overweight rating with a $104 target, while Wells Fargo kept an overweight rating and raised its target to $109. Barclays maintained its overweight rating with a $122 target, and Cantor Fitzgerald kept its overweight rating with a $137 target. RBC Capital maintained a sector perform rating while lowering its target to $75. The stock carries a consensus buy rating from 15 analysts with a mean target price of $100.33.

About PTC Therapeutics, Inc.

PTC Therapeutics, Inc. is a Warren, New Jersey-based biopharmaceutical firm focused on developing and commercializing treatments for children and adults with rare disorders. With nearly 1,000 employees, the company works to bring specialized medicines to patients globally. Tracking insider moves like this gives market watchers a window into how leadership manages personal holdings as the company advances its clinical and commercial pipeline.

Bottom Line

Investors will look to the upcoming earnings report on October 29, 2026, for further updates on the company's financial trajectory. Form 4 filings will continue to show how executives and directors manage their share counts.